Results 211 to 220 of about 64,427 (282)

A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]

PLoS One
Zeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc   +1 more source

Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation [PDF]

, 2004
Paolo Anderlini, Sheetal Sheth, Krystal Hicks, Cindy Ippoliti, Sergio Giralt, Richard E. Champlin   +5 more
openalex   +1 more source

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]

Cancers (Basel)
Boichuk S, Dunaev P, Galembikova A, Valeeva E.   +3 more
europepmc   +1 more source

Imatinib mesylate (STI-571), a c-Abl kinase inhibitor, indirectly blocks receptor tyrosine kinase activation and induces apoptosis in a human cholangiocarcinoma cell line

, 2003
Mihnea V. Chiorean, Jung‐Hwan Yoon, Steven F. Bronk, Scott H. Kaufmann, Gregory J. Gores   +4 more
openalex   +1 more source

Imatinib mesylate effectively combines with chaperone‐rich cell lysate‐loaded dendritic cells to treat bcr‐abl⁺ murine leukemia [PDF]

, 2004
Yi Zeng, Michael W. Graner, Hanping Feng, Gang Li, Emmanuel Katsanis   +4 more
openalex   +1 more source

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

Circulation, 2013
M. Hoeper, R. Barst, R. Bourge, J. Feldman, A. Frost, N. Galiè, M. Gómez-Sánchez, F. Grimminger, E. Grünig, P. Hassoun, N. Morrell, A. Peacock, T. Satoh, G. Simonneau, V. Tapson, F. Torres, D. Lawrence, D. Quinn, H. Ghofrani   +18 more
semanticscholar   +1 more source

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19. [PDF]

Trials, 2022
Atmowihardjo L, Schippers JR, Bartelink IH, Bet PM, van Rein N, Purdy K, Cavalla D, Comberiati V, McElroy A, Snape SD, Bogaard HJ, Heunks L, Juffermans N, Schultz M, Tuinman PR, Bos LDJ, Aman J.   +16 more
europepmc   +1 more source

A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein [PDF]

, 2004
Takatsune Shimizu, Yoshitaka Miyakawa, Satoshi Iwata, Akiko Kuribara, Tony Tiganis, Chikao Morimoto, Yasuo Ikeda, Masahiro Kizaki   +7 more
openalex   +1 more source

Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate [PDF]

, 2004
Peter Reichardt, Udo Schneider, Christian Stroszczynski, Daniel Pink, Peter Hohenberger   +4 more
openalex   +1 more source

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial

Annals of Surgery, 2013
R. DeMatteo, K. Ballman, C. Antonescu, C. Corless, V. Kolesnikova, M. von Mehren, M. McCarter, J. Norton, R. Maki, P. Pisters, G. Demetri, M. Brennan, K. Owzar   +12 more
semanticscholar   +1 more source